Evolus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Evolus and other ETFs, options, and stocks.

About EOLS

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. 

CEO
David Moatazedi
CEODavid Moatazedi
Employees
334
Employees334
Headquarters
Newport Beach, California
HeadquartersNewport Beach, California
Founded
2012
Founded2012
Employees
334
Employees334

EOLS Key Statistics

Market cap
623.13M
Market cap623.13M
Price-Earnings ratio
-14.40
Price-Earnings ratio-14.40
Dividend yield
Dividend yield
Average volume
1.01M
Average volume1.01M
High today
$7.64
High today$7.64
Low today
$7.43
Low today$7.43
Open price
$7.47
Open price$7.47
Volume
63.90K
Volume63.90K
52 Week high
$7.95
52 Week high$7.95
52 Week low
$3.86
52 Week low$3.86

Stock Snapshot

The current Evolus(EOLS) stock price is $7.52, with a market capitalization of 623.13M. The stock trades at a price-to-earnings (P/E) ratio of -14.40.

As of 2026-08-10, Evolus(EOLS) stock has fluctuated between $7.43 and $7.64. The current price stands at $7.52, placing the stock +1.2% above today's low and -1.6% off the high.

Evolus(EOLS) shares are trading with a volume of 63.9K, against a daily average of 1.01M.

In the last year, Evolus(EOLS) shares hit a 52-week high of $7.95 and a 52-week low of $3.86.

In the last year, Evolus(EOLS) shares hit a 52-week high of $7.95 and a 52-week low of $3.86.

EOLS News

Investing.com 3d
Evolus signs licensing deal for Profhilo skin injectable in US - Investing.com

...

Evolus signs licensing deal for Profhilo skin injectable in US - Investing.com
TipRanks 5d
Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. ((EOLS)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Ti...

TipRanks 5d
Evolus reports Q2 EPS (12c), consensus (4c)

Reports Q2 revenue $84.1M, consensus $81.54M. “The increasing momentum of our portfolio focus has resulted in Evolus (EOLS) gaining significant share across inj...

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

More EOLS News

TipRanks 6d
Evolus Expands Estyme Aesthetic Portfolio into New Markets

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own EOLS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.